iStat Biomedical Co., Ltd. - Epigene

iStat, Epigene, Epigenebio, Cervical cancer test, Oral cancer test, Cancer methylation test, Epigenetic IVD assay, Non-invasive early cancer detection, DNA Methylatoin, 日祥, 甲基化基因檢測, 癌症基因檢測

iStat- Epigenetic IVD assay for cancer DNA methylation biomarkers. iStat is a Taiwan-based biotechnology company specialized in the development and manufacturing of high quality gene methylation assay products for the early detection of cervical, oral, and bladder cancers. The company provides innovative IVD products for use in the clinical laboratories and solutions for medication managements. The company is actively seeking distributors in Europe, Middle East, and Latin America, and is discussing licensing potentials with some of the global companies.

Frequently Asked Questions

 

 

DNA methylation is a heritable epigenetic marker involving the covalent transfer of a methyl group to the C-5 position of the cytosine ring of DNA by DNA methyltransferases (DNMTs). Methylation modifies the function of the DNA. When the promoter region of a gene is methylated, expression of the gene is repressed. The researchers have also linked dysregulation in methylation, which contributes to diseases such as cancer.
DNA methylation is an important regulator of gene transcription. However, promoter hypermethylation also plays a major role in tumorigenesis through transcriptional silencing of critical tumor suppressor genes such as PAX1, ZNF582, and so on. These discoveries in the field of DNA methylation in carcinogenesis create new opportunities to identify biomarkers for early detection and personalized treatment of cancer.
In 2003, Prof. Lai give undivided attention to DNA methylation research for cervical cancer screening in National Defense Medical Center. They discover that several genes (PAX1, ZNF582, SOX1, NKX6.1, and so on) have hypermethylation, compared with normal cervical tissue, in cervical cancer. In 2009, National Defense Medical Center licensing the patent of cancer screening method out to iStat.
Cervical cancer starts in the cells lining the cervix. The part of the cervix closest to the body of the uterus is called the endocervix. The part next to the vagina is the exocervix. The 2 main types of cells covering the cervix are squamous cells and glandular cells. These 2 cell types meet at a place called the transformation zone. Most cervical cancers begin in the cells in the transformation zone. The normal cells of the cervix gradually develop pre-cancerous changes (cervical intraepithelial neoplasia (CIN), squamous intraepithelial lesion (SIL), and dysplasia) that turn into cancer.
Women with early cervical cancers and pre-cancers usually have no symptoms. When a pre-cancer becomes a invasive cancer or grows into nearby tissue, the most common symptoms are:
  • Abnormal vaginal bleeding
  • Pain during sex An unusual discharge from the vagina
Some genes have instructions for controlling when our cells grow and divide. Certain genes that promote cell division are called oncogenes. Others that slow down cell division or cause cells to die at the right time are called tumor suppressor genes. Cancers can be caused thought turn on oncogenes or turn off tumor suppressor genes by some risk factor, such as:
  • Human papilloma virus infection
  • Smoking
  • Immunosuppression
  • Chlamydia infection
  • A diet low in fruits and vegetables
  • Being overweight
  • Long-term use of oral contraceptives
  • Intrauterine device use
  • Having multiple full-term pregnancies
  • Being younger than 17 at your first full-term pregnancy
  • Diethylstilbestrol
Cervical cancer screening is an easy way to prevent cervical cancer. Three screening tests can help prevent cervical cancer or find it early.
 
  • DNA methylation test
  • Pap Smear test HPV infection test
The 5-year survival rate refers to the percentage of patients who live at least 5 years after their cancer is diagnosed. The rates below were published in 2010 in the 7th edition of the AJCC staging manual. They are based on data collected by the National Cancer Data Base from people diagnosed between 2000 and 2002.

iStat- Epigenetic IVD assay for cancer DNA methylation biomarkers. iStat is a Taiwan-based biotechnology company specialized in the development and manufacturing of high quality gene methylation assay products for the early detection of cervical, oral, and bladder cancers. The company provides innovative IVD products for use in the clinical laboratories and solutions for medication managements. The company is actively seeking distributors in Europe, Middle East, and Latin America, and is discussing licensing potentials with some of the global companies.
en